ATLANTA, June 23, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer of Alimera, will present at the 2011 BIO Business Forum at 9:15 A.M. ET on Tuesday, June 28, 2011 in Washington, D.C.
The Company slide presentation from this forum will be available on the Investor Relations section of the corporate website at .
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an investigational intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
CONTACT: INVESTOR CONTACT: ICR, LLC John Mills 310-954-1105 John.Mills@icrinc.com
